Healthcare professionals including oncologists, uro-oncologists, urologists, oncology nurses, oncology pharmacists, emergency room staff, and other healthcare professionals providing care to cancer patients, including those working in hospitals, cancer centers, oncology clinics, and pharmacies.

Key messages

  • Severe cases of myocarditis have been reported in patients being treated with TECENTRIQ (atezolizumab) in clinical trials.
  • Healthcare professionals are advised to:
    • monitor patients receiving TECENTRIQ for signs and symptoms of myocarditis.
    • withhold TECENTRIQ therapy in patients with Grade 2 myocarditis.
    • permanently discontinue TECENTRIQ treatment in patients with Grade 3 or 4 myocarditis.
    • administer corticosteroids and/or additional immunosuppressive agents as clinically indicated to TECENTRIQ treated patients who develop myocarditis.
  • The Canadian Product Monograph has been updated to include this new safety information.

For more information go to

Posting date: February 14, 2018